Evaxion sets 2027 financial calendar
The Copenhagen biotech listed five dates for 2027 business updates and its annual meeting, with no new trial or regulatory milestones disclosed.
Evaxion A/S, a Copenhagen-based clinical-stage company developing immunotherapies with what it calls its AI-Immunology platform, issued a press release titled "Evaxion announce 2027 financial calendar" on November 12, 20261.
The filing lists five dates for the coming year. The calendar includes a business update and full year 2026 financial results on March 4, 2027, an Annual General Meeting on April 29, 2027, a business update and first quarter 2027 financial results on May 4, 2027, a business update and second quarter 2027 financial results on August 19, 2027, and a business update and third quarter 2027 financial results on November 18, 2027.1
The release contains no new clinical, regulatory, or financial disclosures beyond the schedule itself. The company describes its platform as one that harnesses artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases, conducting what it calls rapid, efficient and high-quality target discovery, drug design and development.1 It states that it has developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases.1
No cash position, runway statement, trial start, or data readout appears in this filing. The next scheduled disclosure under the calendar is the March 4, 2027 update covering full year 2026 results.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.